A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea

References

• Feeney ER, Mallon PW. HIV and HAART- associated dyslipidemia. Open Cardiovasc Med J 2011;5: 49–63.
   PubMedGoogle Scholar
• May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006;368:451–8.
   PubMed Web of Science ®Google Scholar
• Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007;44:1625–31.
   PubMed Web of Science ®Google Scholar
• Choi HK, Jeong SJ, Lee HS, Chin BS, Choi SH, Han SH, et al. Clinical manifestations for diabetes mellitus in HIV-infected Koreans on highly active antiretroviral therapy. The Korean Journal of Medicine 2008;74:506–14.
   Google Scholar
• Batsis JA, Lopez-Jimenez F. Cardiovascular risk assessment—from individual risk prediction to estimation of global risk and change in risk in the population. BMC Med 2010; 8:29.
   PubMed Web of Science ®Google Scholar
• Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267.
   PubMed Web of Science ®Google Scholar
• Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations?A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999;81: 40–6.
   Google Scholar
• Liu J, Hong Y, D’Agostino RB Sr, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004;291: 2591–9.
   PubMed Web of Science ®Google Scholar
• Marrugat J, D’Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003;57:634–8.
   PubMed Web of Science ®Google Scholar
• Knobel H, Jerico C, Montero M, Sorli ML, Velat M, Guelar A, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007;21:452–7.
   PubMed Web of Science ®Google Scholar
• Law MG, Friis-Moller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006;7:218–30.
   PubMed Web of Science ®Google Scholar
• Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726–34.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560–72.
   PubMed Web of Science ®Google Scholar
• Lee JH, Hong KJ, Wang JS, Kim SS, Kee MK. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62–9.
   Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993–2003.
   PubMed Web of Science ®Google Scholar
• Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?J Acquir Immune Defic Syndr 2002;30:471–7.
   PubMed Web of Science ®Google Scholar
• Kee MK, Lee JH, Kim GJ, Choi BS, Hong KJ, Lee JS, et al. Decrease of initial CD4 + T-cell counts at the time of diagnosis of HIV infection in Korea; 1988–2006. Int J STD AIDS2010;21:120–5.
   Google Scholar
• Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978–82.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010;121:1768–77.
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation 2002;105:310–5.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335:136.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243–51, 4p following 2251.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297:611–9.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.
   PubMed Web of Science ®Google Scholar
• Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, et al. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. Braz J Infect Dis 2010;14:158–66.
   PubMed Web of Science ®Google Scholar
• Minguez Gallego C, Vera-Remartinez EJ, Garcia-Guerrero J, Rincon S, Martinez-Rodenas C, Herrero A. Vascular risk factors in HIV-infected patients in a penitentiary center. Rev Clin Esp 2011;211:9–16.
   PubMed Web of Science ®Google Scholar
• Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev 2009;21:14–27.
   PubMed Web of Science ®Google Scholar
• Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk 2001;8:291–7.
   PubMedGoogle Scholar
• McDonald CL, Kaltman JR. Cardiovascular disease in adult and pediatric HIV/AIDS. J Am Coll Cardiol 2009;54: 1185–8.
   PubMed Web of Science ®Google Scholar
• Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292–8.
   PubMed Web of Science ®Google Scholar
• Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29: 441–9.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010;17:491–501.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35–43.
   PubMed Web of Science ®Google Scholar
• Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007;44:493–9.
   PubMed Web of Science ®Google Scholar
• Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747–8.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 2003;25:2405–18.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17: 1179–93.
   Google Scholar
• Bozzette SA, Ake CF, Tam HK, Phippard A, Cohen D, Scharfstein DO, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008;47:338–41.
   PubMed Web of Science ®Google Scholar